Impact & Innovation
The Institute, together with the Leeds Biomedical Research Centre (Leeds BRC), brings together two large institutions enshrined in a formal research framework agreement, which aims to develop an outstanding reputation for translating basic biomedical research into innovative clinical practice and improved patient care. LIRMM has been built around a novel infrastructure, in which the academic and clinical activities are seamlessly linked.
Leeds is acknowledged as an international leader in inflammatory arthritis. We are the most highly cited rheumatology group in the UK and second in Europe. Over the past 15 years, we have established a rapid referral system for our Yorkshire population of 4.5 million: through this mature network, we have developed well defined patient cohorts enables experimental research for targeted treatments. At the core of the rheumatology success lies exploiting inception cohorts to permit unique experiments in the understanding of the pathogenesis of early inflammatory arthritis (IA), identification of non responder subtypes and the pathophysiology of remission in rheumatoid arthritis (RA) patients. This understanding allows targeting of clinical, imaging and immunological endpoints that have resulted in patients successfully ceasing medication. Innovative studies in immunotherapy, including B-cell depletion and T-cell therapy, have provided a scientific basis for new treatments in inflammatory arthritis.
Our unique clinical, imaging and laboratory infrastructure facilitates interdisciplinary approach in the delivery of responsive, patient centred research. Our clinical research activities are undertaken at Chapel Allerton Hospital (CAH), which was refurbished in 2006 with a £25 million capital investment designed specifically as a seamless environment between multi-disciplinary clinical care and translational research. Research dedicated imaging, motion analysis and bio-sample facilities are housed within or adjacent to the outpatient area.
Central to the research facilities, is the NIHR funded LMBRU Imaging Centre, which has a research dedicated 3 Tesla MRI system with 32 receiver channels, rapid switching gradients and musculoskeletal imaging radiofrequency coils, fusion and 4D ultrasound and image processing facilities. The laboratory facilities are within the Leeds-Wellcome Trust basic science Institute; £23 million JIF-funded building and the adjacent NHS Haematological Malignancy Diagnostic Service (HMDS) at St. Jamess University Hospital. LIRMM is a multidisciplinary Institute with a critical mass of scientists using advanced state of the art equipment and cellular and molecular techniques to study human disease. Facilities include sequencing capabilities, nucleic acid and protein expression analysis, several real time PCR machines, in-situ PCR, immuno-histochemistry, quantitative Western/Northern blots analysis, a seven colour flow cytometer MoFlo and FACS-Vantage cell sorters